This was originally published by News Medical Life Sciences By combining genomic testing and next generation sequencing technology, a new partnership led by RCSI researchers aims to advance predictive tests for multiple myeloma (MM), the second most common blood cancer in Ireland. The study will be carried out at Beaumont Hospital Dublin and run through...Continue Reading
This post was originally published by Cure Specific disease characteristics of, and treatments for, multiple myeloma were not associated with increased mortality risk in patients with multiple myeloma who developed COVID-19, according to data published in Journal of Hematology & Oncology. “Limited studies describing the impact of COVID-19 both in the (United States) and abroad suggest...Continue Reading
This post was originally published by Targeted Oncology C. Ola Landgren, MD, PhD, chief of Myeloma Service and hematologic oncologist at Memorial Sloan Kettering Cancer Center, discusses what is next for chimeric antigen receptor (CAR) T-cell therapy in the multiple myeloma landscape. Landgren thinks the field is about to reach its potential since there are several...Continue Reading
This article was originally published by OncLive In just the past 5 years, incredible progress has been made in multiple myeloma, evidenced by the emergence of novel CD38 antibodies, BCMA-directed treatments, and cereblon E3 ligase modulators (CELMoDs), according to Thomas G. Martin, MD. “We have a lot of options that are coming up. It’s really...Continue Reading
This article was originally published on CBC ‘We still had that sense of community happening out there anyway’ Small but mighty groups of those with multiple myeloma along with their loved ones hit the streets of Halifax and beyond this weekend to raise awareness and funds. They were together, but apart, due to the ongoing pandemic. Julie...Continue Reading
This article originally published by PharmaTimes Online The National Institute for Heath and Care Excellence (NICE) has turned down NHS funding of Celgene’s Revlimid (lenalidomide) as maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma in adults. There is currently no maintenance treatment for newly diagnosed multiple myeloma in people who...Continue Reading
This article was originally published by The Limbic The anti-CD38 mAb daratumumab (Darzalex) has received a positive recommendation from the Pharmaceutical Benefits Advisory Committee (PBAC) for PBS listing as a second line treatment in combination with bortezomib and dexamethasone for patients with multiple myeloma. The drug was recommended on the basis that it should be available...Continue Reading
This article was originally published by Cure Understanding Smoldering Multiple Myeloma Transcript: Kristie L. Kahl: Can you explain what smoldering myeloma is? Dr. Irene Ghobrial: Many patients come in to see us because they have back pain or anemia or kidney problems; however, if we know that every single patient who comes to see us with multiple...Continue Reading
This article was originally published by AJMC Treatment Evolution in Multiple Myeloma Looking at the current state of multiple myeloma management, experts discuss interest in novel therapies and MRD assessment to guide treatment. Transcript Bruce Feinberg, DO: Hello, and welcome to this AJMC® webcast titled “Changing Patterns of Care in Multiple Myeloma.” I’m Dr Bruce Feinberg from...Continue Reading
This article was originally published by Cancer Network The FDA has approved daratumumab (Darzalex) for use in combination with carfilzomib (Kyprolis) and dexamethasone (DKd) to treat adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 previous lines of therapy, according to the Janssen Pharmaceutical Companies of Johnson & Johnson, the...Continue Reading
